CD274 and neoplasm: At that time, IHC using the PD-L1 IHC 22C3 pharmDx assay showed a tumor cell PD-L1 expression percentage of 0% and immune cell PD-L1 expression of 5% (Dako, Inc.)(Figure 2B).